PK assessment
PK profiles of BPI-9016M and its metabolites (M1 and M2-2) in different dose cohorts (300 mg QD, 450 mg QD and 600 mg QD) were evaluated during the continuous administration of BPI-9016M for 28 days in Part A which is also the pharmacokinetics analysis set (PKAS). Serial peripheral blood samples were collected at pre-dose on Cycle 1 Day 8, Cycle 1 Day 15 and Cycle 1 Day 22 for the trough concentration (C